In vitro activity of ceftolozane/tazobactam against Enterobacterales and Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia in Germany.
14. Juni 2023Kresken M, Körber-Irrgang B, Korte-Berwanger M, Pfennigwerth N, Gatermann SG, Wohlfarth E, Seifert H. In vitro activity of ceftolozane/tazobactam against Enterobacterales and Pseudomonas…Multidrug resistance in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa and susceptibility to four last resort antimicrobials, Germany.
14. Juni 2023Kresken M, Wohlfarth E, Wichelhaus TA, Gatermann SG, Seifert H. Multidrug resistance in Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa and susceptibility to four last resort…Genome-based characterisation of colistin-resistant Escherichia coli isolates from human patients and livestock products in Germany.
14. Juni 2023Rackwitz W, Neumann B, Pfennigwerth N, Hunfeld KP, Kresken M, Leistner R, Probst-Kepper M, Fuchs S, Werner G, Pfeifer Y. Genome-based…Determination of a dalbavancin epidemiological cut-off value (ECOFF) for Enterococcus faecium.
14. Juni 2023Weber R, Fleige C, Layer F, Neumann B, Kresken M, Werner G. Determination of a dalbavancin epidemiological cut-off value (ECOFF) for Enterococcus…In vitro activity of dalbavancin against glycopeptide-resistant Enterococcus faecium and coagulase-negative staphylococci recovered from patients in Germany.
14. Juni 2023Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Werner G. In vitro activity of dalbavancin against glycopeptide-resistant Enterococcus faecium and coagulase-negative…The evolution of carbapenem resistance determinants and major epidemiological lineages among carbapenem-resistant Acinetobacter baumannii isolates in Germany
14. Juni 2023Wohlfarth E, Kresken M, Higgins P, Stefanik D, Wille J, Körber-Irrgang B, Seifert H. The evolution of carbapenem resistance determinants and…Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalised patients in Germany: occurrence, characteristics and dalbavancin susceptibility. J Glob Antimicrob Resist. 2022 Mar;28:102-107. doi: 10.1016/j.jgar.2021.12.016.
31. Mai 2023Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G Kresken M, Pfeifer Y, Werner G. Comparative…Study Group ‘Antimicrobial Resistance’ of the Paul-Ehrlich-Society for Chemotherapy. Glycopeptide resistance in Enterococcus spp. and coagulase-negative staphylococci from hospitalized patients in Germany: occurrence, characteristics, and susceptibility to dalbavancin. J Glob Antimicrob Resist. 2021 Dec 24:S2213-7165(21)00289-7
31. Mai 2023Kresken M, Klare I, Wichelhaus TA, Wohlfarth E, Layer-Nicolaou F, Neumann B, Werner G https://doi.org/10.1016/j.jgar.2021.12.016Determination of a Tentative Epidemiological Cut-Off Value (ECOFF) for Dalbavancin and Enterococcus faecium. Antibiotics 2021, 10(8), 915
31. Mai 2023Weber RE, Fleige C, Layer F, Neumann B, Kresken M, Werner, G https://doi.org/10.3390/antibiotics10080915In vitro activity of ceftazidime/avibactam against ceftazidime-resistant Enterobacterales and Pseudomonas aeruginosa from hospitalised patients in Germany. J Global Antimicrob Resist. 2021;25: 337–338
31. Mai 2023Kresken M, Korte-Berwanger M, Pfennigwerth N, Gatermann SG.